Background: Five severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines are approved in North America and/or Europe: Pfizer/BioNTech, Moderna, Janssen, Oxford-AstraZeneca, and Novavax. Other vaccines have been developed, including Sinopharm, SinoVac, QazVac, Covaxin, Soberana, Zifivax, Medicago, Clover, and Cansino, but they are not approved in high-income countries. This meta-analysis compared the efficacy of US Food and Drug Administration (FDA)/European Medicines Agency (EMA)-approved and -unapproved vaccines in randomized clinical trials (RCTs).
Methods: A systematic review of trial registries identified RCTs of SARS-CoV-2 vaccines. Risk of bias was assessed using the Cochrane tool (RoB 2). In the meta-analysis, relative risks of symptomatic infection and severe disease were compared for each vaccine versus placebo, using Cochrane-Mantel Haenszel Tests (random effects method).
Results: Twenty-two RCTs were identified and 1 was excluded for high-risk of bias. Ten RCTs evaluated 5 approved vaccines and 11 RCTs evaluated 9 unapproved vaccines. In the meta-analysis, prevention of symptomatic infection was 84% (95% confidence interval [CI], 68%-92%) for approved vaccines versus 72% (95% CI, 66%-77%) for unapproved vaccines, with no significant difference between vaccine types ( = .12). Prevention of severe SARS-CoV-2 infection was 94% (95% CI, 75%-98%) for approved vaccines versus 86% (95% CI, 76%-92%) for unapproved vaccines ( = .33). The risk of serious adverse events was similar between vaccine types ( = .12).
Conclusions: This meta-analysis of 21 RCTs in 390 459 participants showed no significant difference in efficacy between the FDA/EMA-approved and -unapproved vaccines for symptomatic or severe infection. Differences in study design, endpoint definitions, variants, and infection prevalence may have influenced results. New patent-free vaccines could lower costs of worldwide SARS-CoV-2 vaccination campaigns significantly.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9452066 | PMC |
| http://dx.doi.org/10.1093/ofid/ofac408 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Use of Chemical Tracers in Population Studies-A Scoping Review.
Animals (Basel)
November 2024
College of Veterinary Medicine, Iowa State University, Ames, IA 50011, USA.
A highly invasive species, free-ranging often negatively impact the ecosystem and are capable of spreading a number of impactful pathogens to domestic livestock. Measures taken to ameliorate these impacts and/or control population size are based on the delivery of oral baits containing bioactive chemicals or vaccines, e.g.
View Article and Find Full Text PDFPublic and health care provider attitudes, understanding, and behaviors regarding emergency use authorizations: a scoping literature review.
BMC Public Health
October 2024
Department of Family Science & Maryland Center for Health Equity, School of Public Health, University of Maryland, College Park, MD, USA.
Article Synopsis
- The study examines how well the public and health care providers understand emergency use authorizations (EUAs) for unapproved products or uses during health emergencies as defined by federal law.
- A scoping review of existing literature found 13 studies discussing attitudes and understanding of EUAs, but none focused on promoting these products.
- Results indicate that both the public and health care providers are unclear about EUAs, raising safety concerns and potentially decreasing their willingness to use such treatments or vaccines.
Bladder-sparing Therapy for Bacillus Calmette-Guérin-unresponsive Non-muscle-invasive Bladder Cancer: International Bladder Cancer Group Recommendations for Optimal Sequencing and Patient Selection.
Eur Urol
December 2024
Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address:
Article Synopsis
- There has been an increase in agents for treating bacillus Calmette-Guérin-unresponsive (BCG-U) non-muscle-invasive bladder cancer (NMIBC), and there is a pressing need for patient and therapy selection guidelines due to a lack of randomized trials.
- A global expert committee developed recommendations through literature reviews and a voting process, refining these guidelines during a live meeting in August 2023, achieving over 75% agreement on the final recommendations.
- No single optimal treatment exists for BCG-U patients; personalized treatment based on individual preferences, tumor characteristics, and available agent data is essential, with specific options recommended for carcinoma in situ and papillary-only tumors, and clinical trial participation encouraged.
Personalized Dosing of Medicines for Children: A Primer on Pediatric Pharmacometrics for Clinicians.
Paediatr Drugs
July 2024
Department of Clinical Pharmacy and Biochemistry, Institute of Pharmacy, Freie Universität Berlin, Berlin, Germany.
Article Synopsis
- The common off-label use of drugs in children is largely due to challenges in pediatric drug research, including practical, ethical, and financial issues.
- Pharmacometrics, which applies mathematical models to understand drug effects, has potential to improve pediatric drug development by personalizing dosing and speeding up the approval process.
- Key methods in pharmacometrics include population pharmacokinetic modeling for individual variability and physiologically based pharmacokinetic models for limited data scenarios; effective use of these models requires collaboration between clinicians and pharmacometricians, alongside new data-gathering techniques.
The practice of using repurposed medications as chemoprophylaxis for COVID-19 by healthcare workers in a tertiary hospital in Southern Nigeria.
Afr Health Sci
September 2023
Department of Internal medicine, University of Uyo teaching hospital, Uyo, Akwa Ibom state, Nigeria.
Background: Coronavirus disease 2019 (COVID-19) is a viral infection that has been reported in virtually every country. Healthcare workers (HCW) are more at risk of COVID-19 than the general population making them a priority group for vaccination. Before the roll out of COVID-19 vaccines in Nigeria, some HCW were using some repurposed, unapproved drugs to possibly prevent the disease.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!